Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02326194
Recruitment Status : Completed
First Posted : December 25, 2014
Last Update Posted : August 28, 2015
Sponsor:
Collaborators:
Beijing Institute of Biotechnology
Tianjin Cansino Biotechnology Inc
Information provided by (Responsible Party):
Fengcai Zhu, Jiangsu Province Centers for Disease Control and Prevention

Tracking Information
First Submitted Date  ICMJE December 22, 2014
First Posted Date  ICMJE December 25, 2014
Last Update Posted Date August 28, 2015
Study Start Date  ICMJE December 2014
Actual Primary Completion Date February 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 22, 2014)
  • Occurrence of adverse reactions after vaccination. [ Time Frame: within 7 days after the vaccination ]
    Occurrence of adverse reactions within 7 days after vaccination with the Ebola Zaire vaccine (Ad5-EBOV).
  • Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 28 days after the vaccination ]
    Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV) as measured by ELISA.
  • Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 28 days after the vaccination ]
    Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV) as measured by intracellular cytokine staining assays (ICS)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 22, 2014)
  • Occurrence of adverse events after the vaccination. [ Time Frame: within 28 days after the vaccination ]
    Occurrence of adverse events within 28 days after vaccination with the Ebola Zaire vaccine (Ad5-EBOV).
  • Changes of the laboratory examinations after vaccination. [ Time Frame: day 0-28 after the vaccination ]
    Changes of the laboratory examinations after vaccination with the Ebola Zaire vaccine (Ad5-EBOV) on day 3, 14 and 28.
  • Occurrence of serious adverse events after the vaccination. [ Time Frame: within 6 months after the vaccination ]
    Occurrence of serious adverse events within 6 months after the vaccination with the Ebola Zaire vaccine (Ad5-EBOV).
  • Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 168 days after the vaccination ]
    Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 168 as measured by ELISA.
  • Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 168 days after the vaccination ]
    Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 168 as measured by intracellular cytokine staining assays (ICS).
  • Anti-adenovirus neutralizing antibody responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 168 days after the vaccination ]
    Anti-adenovirus neutralizing antibody responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 168.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: December 22, 2014)
  • Changes of the laboratory examinations after vaccination. [ Time Frame: day 168 after the vaccination ]
    Changes of the laboratory examinations after vaccination with the Ebola Zaire vaccine (Ad5-EBOV) at day 168.
  • Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 3-112 days after the vaccination ]
    Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 3, 7, 14, 56 and 112 as measured by ELISA.
  • Anti-adenovirus neutralizing antibody responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: 3-56 days after the vaccination ]
    Anti-adenovirus neutralizing antibody responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 3, 7, 14, 56 and 112.
  • Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: day 7-112 after the vaccination ]
    Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 7, 14, 56 and 112 as measured by intracellular cytokine staining assays (ICS).
  • Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV). [ Time Frame: day 0-168 after the vaccination ]
    Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV) at day 0, 28 and 168 as measured by ELISpot.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
Official Title  ICMJE A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China
Brief Summary

Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain, with GP homology of the gene was only 97.6%, compared to the GP gene of the strain in 1976. This investigational Ad5-EBOV vaccine was developed according to the 2014 epidemic Zaire strain and formulated as freeze-dry products which could be stored at 4℃.

This is a single center, double-blind, placebo control, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Ebola Virus Disease
Intervention  ICMJE
  • Biological: Low dose Ebola Zaire vaccine (Ad5-EBOV)
    one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
  • Biological: High dose Ebola Zaire vaccine (Ad5-EBOV)
    two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
  • Biological: placebo (one dose)
    placebo, one doses
  • Biological: placebo (two doses)
    placebo, two doses, with one dose to each arm at a same time.
Study Arms  ICMJE
  • Placebo Comparator: Placebo group (one shot)
    one dose
    Intervention: Biological: placebo (one dose)
  • Placebo Comparator: Placebo group (two shots)
    two doses, with one dose to each arm at a same time.
    Intervention: Biological: placebo (two doses)
  • Experimental: Low dose vaccine group
    one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
    Intervention: Biological: Low dose Ebola Zaire vaccine (Ad5-EBOV)
  • Experimental: High dose vaccine group
    two doses, high dose, with one dose to each arm at a same time
    Intervention: Biological: High dose Ebola Zaire vaccine (Ad5-EBOV)
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 22, 2014)
120
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 2015
Actual Primary Completion Date February 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Aged between 18 and 60 years.
  • Able to understand the content of informed consent and willing to sign the informed consent
  • Able and willing to complete all the secluded study process during the whole study follow-up period (about 6 months).
  • A body mass index (BMI) <35
  • Hemoglobin 110-150g/L for female, and 120-160g/L for male.
  • White blood cells (WBC) 4.0-10.0×109 cells/L
  • Total lymphocyte Count 0.8-4.5×109 cells/L
  • Platelets 100-300×109 cells/L
  • Alanine aminotransferase (ALT) 0-40U/L
  • Serum creatinine 44-106μmol/L
  • Partial thromboplastin time (PTT) 20-40 seconds
  • Prothrombin time (PT) 10-14 seconds
  • Negative in HIV diagnostic blood test
  • Axillary temperature ≤37.0°C on the day of enrollment
  • General good health as established by medical history and physical examination.

Exclusion Criteria:

  • Family history of seizure, epilepsy, brain or mental disease
  • Subject that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV vaccine, such as mannitol
  • Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months
  • Any acute fever disease or infections in last 7 days
  • Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease
  • Hereditary angioneurotic edema or acquired angioneurotic edema
  • Urticaria in last one year
  • Asplenia or functional asplenia
  • Platelet disorder or other bleeding disorder may cause injection contraindication
  • Faint at the sight of blood or needles.
  • Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months
  • Prior administration of blood products in last 4 months
  • Prior administration of other research medicines in last 1 month
  • Prior administration of attenuated vaccine in last 1 month
  • Prior administration of inactivated vaccine in last 14 days
  • Current anti-tuberculosis prophylaxis or therapy
  • Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02326194
Other Study ID Numbers  ICMJE JSVCT020
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Fengcai Zhu, Jiangsu Province Centers for Disease Control and Prevention
Study Sponsor  ICMJE Jiangsu Province Centers for Disease Control and Prevention
Collaborators  ICMJE
  • Beijing Institute of Biotechnology
  • Tianjin Cansino Biotechnology Inc
Investigators  ICMJE Not Provided
PRS Account Jiangsu Province Centers for Disease Control and Prevention
Verification Date August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP